海思科医药集团股份有限公司 关于持股 5%以上股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日接到 公司股东范秀莲女士的通知，获悉其所持有本公司的部分股份被质押， 具体事项如下： 证券代码：002653 证券简称：海思科 公告编号：2025-132 本次质押股份未负担重大资产重组等业绩补偿义务。 二、股东股份累计质押的情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如 下： | | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股 | 持股 | 本次质押前 | 本次质押后 | 占其所 | 占公司 | | | | | | | 数量 | | 质押股份数 | 质押股份数 | 持股份 | 总股本 | 已质押股 | 占已 | 未质押股 | 占未 | | 名称 | （万股） | 比例 | 量（万股） | 量（万 ...

每经头条（nbdtoutiao）——海南封关政策红利全解析：零关税、低个税、投资准入放宽、跨境资金自 由、创业扶持…… 2025年1至6月份，海思科的营业收入构成为：医药行业占比99.14%，其他业务占比0.86%。 截至发稿，海思科市值为577亿元。 每经AI快讯，海思科（SZ 002653，收盘价：51.5元）12月18日晚间发布公告称，海思科医药集团股份 有限公司于2025年12月18日收到政府补助1.2亿元，占2024年度经审计归属于上市公司股东净利润的 30.34%。 （记者 曾健辉） ...

Policy Developments - Jiangxi Province has introduced 13 measures to promote the high-quality development of the pharmaceutical retail chain industry, including support for enterprise integration, simplified approval processes, and encouragement of innovative business models [1] - The new policies aim to address industry pain points, such as supporting mergers and acquisitions, and promoting health service extensions like chronic disease management [1] Medical Device Approvals - The National Medical Products Administration has approved two innovative medical devices: a proton therapy system for treating malignant tumors and a deep brain stimulation system for opioid addiction treatment [2] Clinical Trials - Haikang announced that its subsidiary received clinical trial approval for four innovative drugs targeting inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [3] Capital Market Developments - Changchun High-tech signed an exclusive licensing agreement for the GenSci098 injection project, potentially earning up to $1.365 billion in milestone payments [4][5] Industry Collaborations - Sunshine Nuohuo has partnered with Peking University to establish a joint laboratory focused on innovative drug development, particularly in cell and gene therapy [7] Regulatory Actions - The Shanghai Consumer Protection Committee has addressed issues related to Antarctic krill oil products from Beijing Tongrentang, highlighting quality control failures and potential misrepresentation [10][11]

Group 1 - The first invasive brain-computer interface product for treating drug addiction has been approved in China, marking a significant milestone in the field of mental health treatment [1] - The product is designed for severe opioid addiction patients and provides a new option for treatment, filling a technological gap in physical interventions for opioid addiction [1] - The approval indicates that China's brain-computer interface products are at the forefront of global applications in treating mental illnesses, although long-term safety and commercial performance remain to be observed [1] Group 2 - Four new class 1 innovative drugs from a subsidiary of Haikang have received clinical trial approval, showcasing the breadth of the company's research and development pipeline [2] - The approval of multiple new drugs in a short period reflects the company's commitment to innovation, but the long and complex drug development cycle poses high risks and uncertainties [2] - Investors are advised to monitor the clinical progress of these new drugs closely due to the inherent uncertainties in the drug development process [2] Group 3 - Sunshine Nuohua has announced a collaboration with Peking University to establish a joint laboratory focused on innovative drug development, particularly in cell and gene therapy [3] - This partnership aims to enhance research depth and technological foresight, aligning with the industry trend of integrating production, education, and research in innovative drug development [3] - The collaboration is expected to contribute to long-term capability building, although immediate performance impacts may not be realized [3]

Group 1 - The first invasive brain-machine interface product for treating drug addiction has been approved in China, marking a significant milestone in the field of mental health treatment [1] - The product is designed for patients with severe opioid addiction and provides a new option for relapse prevention through deep brain stimulation [1] - This approval highlights China's leading position in the application of brain-machine interface technology for treating mental disorders [1] Group 2 - A subsidiary of Haikang has received clinical trial approval for four innovative chemical drugs, indicating a broad research and development pipeline [2] - The approval of multiple first-class new drugs reflects the company's commitment to innovation, although the long and complex drug development process carries inherent risks [2] - Investors are advised to monitor the clinical progress of these new drugs due to potential uncertainties [2] Group 3 - Sunshine Nuohua has announced a collaboration with Peking University to establish a joint laboratory focused on innovative drug development [3] - The partnership aims to enhance research capabilities in cutting-edge fields such as cell and gene therapy, aligning with industry trends of integrating academia and industry [3] - This collaboration is expected to contribute to long-term capacity building in drug development, although immediate financial returns may not be realized [3]

Core Viewpoint - The company, Haishi Ke, announced that its subsidiary, Shanghai Haishi Shengnuo Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of four drug candidates [2] Group 1: Clinical Trial Approvals - The approved drug candidates include HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [2] - The clinical trial applications were reviewed and found to meet the requirements for drug registration, allowing the company to proceed with the trials [2] - The approval is significant as it indicates progress in the company's drug development pipeline, with trials set to be conducted starting from October 2025 [2]

Group 1 - Action Education plans to repurchase shares worth between 20 million to 25 million yuan at a price not exceeding 45 yuan per share for employee stock ownership plans or equity incentives [1] - Fulin Technology's shareholders plan to reduce their holdings by up to 2% of the company's total shares, amounting to a maximum of 24.44 million shares starting from December 22, 2025 [2] - Huashu shares' shareholders intend to reduce their holdings by up to 1% of the company's total shares, which is a maximum of 35.94 million shares [3] Group 2 - Silan Microelectronics has obtained a filing certificate for its 12-inch high-end analog integrated circuit chip manufacturing production line project, with an investment of 10 billion yuan and a monthly production capacity of 20,000 wafers [4] - Aerospace Information confirms that its main business does not involve commercial aerospace and that its operations are normal without significant changes [5] - Qinglong Pipe Industry signed a supply contract worth 294 million yuan for PCCP and pressure steel pipes, accounting for 10.43% of its 2024 revenue [6] Group 3 - Huaxin Precision plans to invest up to 1 billion yuan of idle funds in low-risk financial products [7] - Hainan Rubber received insurance compensation totaling approximately 26.65 million yuan for rubber income and tree insurance [8] - Lianmei Holdings announced the suspension of its subsidiary Fulin Thermal Power due to economic slowdown and reduced customer demand [9] Group 4 - Ruifeng Bank has been approved to issue up to 2.5 billion yuan in secondary capital bonds to enhance its capital and risk resistance [11] - China Pacific Insurance reported a 9.4% year-on-year increase in premium income for its life insurance subsidiary, totaling 250.32 billion yuan [12] - Sunshine Nuohuo signed an agreement with Peking University to establish a joint laboratory for innovative drug development [13] Group 5 - Century Huatong completed the cancellation of 56.12 million repurchased shares, reducing its total share capital from 7.428 billion to 7.372 billion shares [14] - Yaxin Security received a government subsidy of 3 million yuan [15] - Haili Biology's subsidiary received registration certification for a bone repair material in Indonesia [16] Group 6 - Yian Technology's subsidiary secured a major project for magnesium alloy components worth 430 million yuan, expected to start production by the end of March 2026 [17] - Jiangte Electric plans to contest the proposed cancellation of its lithium-containing mining rights [18] - COFCO Technology announced the resignation of its deputy general manager due to work changes [19] Group 7 - Fangsheng Pharmaceutical passed the GMP compliance inspection for its raw material production lines [21] - Bohai Ferry announced the resignation of two deputy general managers for personal and age-related reasons [22] - ST Fuhua appointed a new general manager [23] Group 8 - Huazhong CNC received project funding of 17.7 million yuan, accounting for 31.97% of its audited net profit for 2024 [24] - Oppein Home used 15 million yuan of idle funds to purchase a large time deposit with a 0.9% annual yield [25] - China General Nuclear Power's Ningde Unit 6 has begun full construction, utilizing Hualong One technology with a capacity of 1210 MW [26] Group 9 - Jiayuan Technology's chairman has had the investigation order lifted, and the company is operating normally [27] - Fulaixin Materials' application for a specific stock issuance has been approved by the Shanghai Stock Exchange [28] - Shuhua Sports plans to invest up to 500 million yuan in a health industry park project [29] Group 10 - Rhine Biology's stock will continue to be suspended due to ongoing control change and asset acquisition plans [30] - Haishi Science received approval for clinical trials for four innovative drugs targeting various diseases [31] - Hangcai Co. plans to repurchase shares worth between 50 million to 100 million yuan at a price not exceeding 80 yuan per share [32] Group 11 - Yinxin Technology received a cash dividend of 18 million yuan from its subsidiary [33] - Tianfulong plans to increase its wholly-owned subsidiary's capital by 580 million yuan [34] - Poly United's subsidiary won a bid for a stripping project worth 1.528 billion yuan [35] Group 12 - Minglida's deputy general manager resigned due to health reasons [36] - ST Guohua appointed a new deputy general manager [37] - China Xidian's subsidiaries won contracts totaling 1.005 billion yuan for Southern Power Grid projects [38]

Core Viewpoint - The company, Haikang (002653.SZ), announced that its subsidiary, Shanghai Haikang Shennuo Pharmaceutical Technology Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for four new drugs, indicating progress in its drug development pipeline [1]. Group 1: Drug Approvals - The National Medical Products Administration has approved clinical trials for four drugs: HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [1]. - The approved drugs are classified as Class 1 chemical drugs according to the regulations set forth in the announcement on chemical drug registration classification [1]. Group 2: Drug Details - HSK45019 is a tablet intended for the treatment of inflammatory bowel disease, with acceptance numbers CXHL2501072 and CXHL2501073 [2]. - HSK50042 is a tablet aimed at respiratory system diseases, with acceptance numbers CXHL2501080 and CXHL2501081 [2]. - HSK55718 is an injectable drug for acute pain, with acceptance numbers CXHL2501077 and CXHL2501078 [2]. - HSK36357 is a capsule for muscular dystrophy, with acceptance numbers CXHL2501059 and CXHL2501060 [2].

Core Viewpoint - The company, Haikang (002653.SZ), announced that its subsidiary, Shanghai Haikang Shennuo Pharmaceutical Technology Co., Ltd., has received clinical trial approval for four innovative drugs from the National Medical Products Administration of China [2] Group 1: Drug Approvals - The approved drugs include HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [2] - These drugs are intended for the treatment of inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [2] - All drugs are classified as Class 1 chemical drugs and possess independent intellectual property rights [2] Group 2: R&D Considerations - The company has highlighted that the research and development of innovative drugs involves long cycles, multiple stages, and high risks, indicating the uncertainties involved [2]

Core Viewpoint - The company has received approval for clinical trials of multiple drug candidates from the National Medical Products Administration, indicating progress in its research and development efforts [1] Group 1: Company Developments - The subsidiary Shanghai Hisun Shennuo Pharmaceutical Technology Co., Ltd. has been granted the Clinical Trial Approval Notice for HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [1] - The approved drug candidates target various indications, including inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [1]